左旋多巴剂量和体重对帕金森病流行人群运动障碍的影响。

The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.

机构信息

Department of Medicine, North Tyneside General Hospital, Rake Lane, North Shields, Tyne and Wear NE29 8NH, UK.

出版信息

Parkinsonism Relat Disord. 2011 Jan;17(1):27-9. doi: 10.1016/j.parkreldis.2010.10.005. Epub 2010 Nov 3.

DOI:10.1016/j.parkreldis.2010.10.005

PMID:21051272

Abstract

AIMS AND OBJECTIVES

We aimed to investigate the effect of active dose and dose per kilogram (kg) of body weight of levodopa on the occurrence of dyskinesia within a prevalent population of people with PD.

METHODS

Of 106 prevalent cases, 75 (70.8%; 38 males, 37 females) agreed to assessment by a member of the research team. Demographic information, weight and height were recorded. Patients were assessed using a range of rating scales including the Unified Parkinson's Disease Rating Scale. Patients were asked specifically: 'Do you have, or have you ever had, dyskinesia?'.

RESULTS

Nine patients (12.0%) reported dyskinesia. Patient reported dyskinesia was significantly associated with greater years since diagnosis (r=0.309, p=0.007), higher levodopa equivalent dose (r=0.406, p<0.001) and levodopa equivalent dose per kg body weight (r=0.375, p<0.001). Using logistic regression, active levodopa dose, unadjusted for body weight, was an independent predictor of dyskinesia.

CONCLUSIONS

Adjusting levodopa dose for body weight did not increase its degree of correlation with patient reported dyskinesia.

摘要

目的和目标

我们旨在研究左旋多巴的活性剂量和每公斤体重剂量对 PD 流行人群中运动障碍发生的影响。

方法

在 106 例现患病例中，有 75 例（70.8%；38 名男性，37 名女性）同意由研究团队成员进行评估。记录人口统计学信息、体重和身高。使用一系列评分量表对患者进行评估，包括统一帕金森病评定量表。特别询问患者：“您是否有或曾经有过运动障碍？”

结果

有 9 名患者（12.0%）报告有运动障碍。患者报告的运动障碍与诊断后年限更长（r=0.309，p=0.007）、左旋多巴等效剂量更高（r=0.406，p<0.001）和左旋多巴等效剂量/公斤体重（r=0.375，p<0.001）显著相关。使用逻辑回归，未根据体重调整的左旋多巴活性剂量是运动障碍的独立预测因子。